JP2015526074A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015526074A5 JP2015526074A5 JP2015524417A JP2015524417A JP2015526074A5 JP 2015526074 A5 JP2015526074 A5 JP 2015526074A5 JP 2015524417 A JP2015524417 A JP 2015524417A JP 2015524417 A JP2015524417 A JP 2015524417A JP 2015526074 A5 JP2015526074 A5 JP 2015526074A5
- Authority
- JP
- Japan
- Prior art keywords
- biomarkers
- subject
- jak
- cish
- socs2
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000090 biomarker Substances 0.000 claims description 59
- 238000000034 method Methods 0.000 claims description 59
- 230000014509 gene expression Effects 0.000 claims description 39
- 239000003112 inhibitor Substances 0.000 claims description 36
- 101000617830 Homo sapiens Sterol O-acyltransferase 1 Proteins 0.000 claims description 32
- 102100021993 Sterol O-acyltransferase 1 Human genes 0.000 claims description 32
- 101000697584 Streptomyces lavendulae Streptothricin acetyltransferase Proteins 0.000 claims description 32
- 102100032218 Cytokine-inducible SH2-containing protein Human genes 0.000 claims description 26
- 101000943420 Homo sapiens Cytokine-inducible SH2-containing protein Proteins 0.000 claims description 26
- 101001064870 Homo sapiens Lon protease homolog, mitochondrial Proteins 0.000 claims description 26
- 101000595531 Homo sapiens Serine/threonine-protein kinase pim-1 Proteins 0.000 claims description 26
- 102100031955 Lon protease homolog, mitochondrial Human genes 0.000 claims description 26
- 101000687808 Homo sapiens Suppressor of cytokine signaling 2 Proteins 0.000 claims description 24
- 102100024784 Suppressor of cytokine signaling 2 Human genes 0.000 claims description 24
- 102100027641 DNA-binding protein inhibitor ID-1 Human genes 0.000 claims description 20
- 101001081590 Homo sapiens DNA-binding protein inhibitor ID-1 Proteins 0.000 claims description 20
- 108020004999 messenger RNA Proteins 0.000 claims description 20
- 239000012472 biological sample Substances 0.000 claims description 18
- 101001023833 Homo sapiens Neutrophil gelatinase-associated lipocalin Proteins 0.000 claims description 16
- 102100035405 Neutrophil gelatinase-associated lipocalin Human genes 0.000 claims description 16
- 208000002250 Hematologic Neoplasms Diseases 0.000 claims description 15
- 150000003839 salts Chemical class 0.000 claims description 10
- -1 EPOR Proteins 0.000 claims description 9
- 206010066476 Haematological malignancy Diseases 0.000 claims description 9
- 102100023226 Early growth response protein 1 Human genes 0.000 claims description 8
- 101001049697 Homo sapiens Early growth response protein 1 Proteins 0.000 claims description 8
- HFNKQEVNSGCOJV-OAHLLOKOSA-N ruxolitinib Chemical group C1([C@@H](CC#N)N2N=CC(=C2)C=2C=3C=CNC=3N=CN=2)CCCC1 HFNKQEVNSGCOJV-OAHLLOKOSA-N 0.000 claims description 5
- 239000000523 sample Substances 0.000 claims description 5
- 230000005540 biological transmission Effects 0.000 claims description 4
- 208000032839 leukemia Diseases 0.000 claims description 4
- 238000011287 therapeutic dose Methods 0.000 claims description 4
- 206010025323 Lymphomas Diseases 0.000 claims description 3
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 2
- 239000003795 chemical substances by application Substances 0.000 claims description 2
- 201000000050 myeloid neoplasm Diseases 0.000 claims description 2
- FVSKHRXBFJPNKK-UHFFFAOYSA-N propionitrile Chemical compound CCC#N FVSKHRXBFJPNKK-UHFFFAOYSA-N 0.000 claims description 2
- 230000004043 responsiveness Effects 0.000 claims description 2
- 239000003550 marker Substances 0.000 claims 1
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 3
- BLLAEKRDPJDWAJ-OAHLLOKOSA-N 4-[1-[(1R)-1-cyclopentylpropyl]pyrazol-4-yl]-7H-pyrrolo[2,3-d]pyrimidine Chemical group N1=CN=C(C2=C1NC=C2)C=1C=NN(C=1)[C@H](CC)C1CCCC1 BLLAEKRDPJDWAJ-OAHLLOKOSA-N 0.000 description 2
- 208000031261 Acute myeloid leukaemia Diseases 0.000 description 2
- 208000003950 B-cell lymphoma Diseases 0.000 description 2
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 description 2
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 description 2
- 230000004547 gene signature Effects 0.000 description 2
- 201000005962 mycosis fungoides Diseases 0.000 description 2
- 150000002825 nitriles Chemical class 0.000 description 2
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 description 1
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 description 1
- 206010073478 Anaplastic large-cell lymphoma Diseases 0.000 description 1
- 208000036170 B-Cell Marginal Zone Lymphoma Diseases 0.000 description 1
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 description 1
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 1
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 description 1
- 206010061850 Extranodal marginal zone B-cell lymphoma (MALT type) Diseases 0.000 description 1
- 208000017604 Hodgkin disease Diseases 0.000 description 1
- 208000021519 Hodgkin lymphoma Diseases 0.000 description 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 description 1
- 208000032004 Large-Cell Anaplastic Lymphoma Diseases 0.000 description 1
- 206010052178 Lymphocytic lymphoma Diseases 0.000 description 1
- 201000003791 MALT lymphoma Diseases 0.000 description 1
- 201000003793 Myelodysplastic syndrome Diseases 0.000 description 1
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 description 1
- 208000037538 Myelomonocytic Juvenile Leukemia Diseases 0.000 description 1
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 1
- 208000027190 Peripheral T-cell lymphomas Diseases 0.000 description 1
- 208000007452 Plasmacytoma Diseases 0.000 description 1
- 208000009359 Sezary Syndrome Diseases 0.000 description 1
- 208000021388 Sezary disease Diseases 0.000 description 1
- 208000031672 T-Cell Peripheral Lymphoma Diseases 0.000 description 1
- 206010042971 T-cell lymphoma Diseases 0.000 description 1
- 208000027585 T-cell non-Hodgkin lymphoma Diseases 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 208000037832 acute lymphoblastic B-cell leukemia Diseases 0.000 description 1
- 208000037833 acute lymphoblastic T-cell leukemia Diseases 0.000 description 1
- 206010002449 angioimmunoblastic T-cell lymphoma Diseases 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 description 1
- 201000003444 follicular lymphoma Diseases 0.000 description 1
- 201000009277 hairy cell leukemia Diseases 0.000 description 1
- 201000005787 hematologic cancer Diseases 0.000 description 1
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 description 1
- 201000005992 juvenile myelomonocytic leukemia Diseases 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 201000011649 lymphoblastic lymphoma Diseases 0.000 description 1
- 208000003747 lymphoid leukemia Diseases 0.000 description 1
- 201000007924 marginal zone B-cell lymphoma Diseases 0.000 description 1
- 208000021937 marginal zone lymphoma Diseases 0.000 description 1
- 201000007925 mature T-cell and NK-cell lymphoma Diseases 0.000 description 1
- 208000020968 mature T-cell and NK-cell non-Hodgkin lymphoma Diseases 0.000 description 1
- 210000001978 pro-t lymphocyte Anatomy 0.000 description 1
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261676484P | 2012-07-27 | 2012-07-27 | |
| US61/676,484 | 2012-07-27 | ||
| US201361769271P | 2013-02-26 | 2013-02-26 | |
| US61/769,271 | 2013-02-26 | ||
| US201361829327P | 2013-05-31 | 2013-05-31 | |
| US61/829,327 | 2013-05-31 | ||
| PCT/US2013/051824 WO2014018632A1 (en) | 2012-07-27 | 2013-07-24 | Prediction of treatment response to jak/stat inhibitor |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2015526074A JP2015526074A (ja) | 2015-09-10 |
| JP2015526074A5 true JP2015526074A5 (enExample) | 2016-09-08 |
Family
ID=48906529
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015524417A Pending JP2015526074A (ja) | 2012-07-27 | 2013-07-24 | Ｊａｋ／ｓｔａｔ阻害剤に対する治療反応の予測 |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US20150299796A1 (enExample) |
| EP (1) | EP2877596A1 (enExample) |
| JP (1) | JP2015526074A (enExample) |
| KR (1) | KR20150038241A (enExample) |
| CN (1) | CN104508149A (enExample) |
| AU (2) | AU2013295855A1 (enExample) |
| BR (1) | BR112015001521A2 (enExample) |
| CA (1) | CA2880198A1 (enExample) |
| CL (1) | CL2015000192A1 (enExample) |
| HK (1) | HK1205198A1 (enExample) |
| IL (1) | IL236897A0 (enExample) |
| MX (1) | MX2015001269A (enExample) |
| PH (1) | PH12015500169A1 (enExample) |
| RU (1) | RU2015106714A (enExample) |
| SG (1) | SG11201500261VA (enExample) |
| TN (1) | TN2015000019A1 (enExample) |
| TW (1) | TW201409030A (enExample) |
| WO (1) | WO2014018632A1 (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3049442A4 (en) | 2013-09-26 | 2017-06-28 | Costim Pharmaceuticals Inc. | Methods for treating hematologic cancers |
| UA122479C2 (uk) | 2014-01-24 | 2020-11-25 | Дана-Фарбер Кенсер Інстітьют, Інк. | Виділена молекула антитіла, яка зв’язується з людським білком програмованої смерті-1 (pd-1) |
| PL3099717T3 (pl) | 2014-01-31 | 2019-10-31 | Novartis Ag | Cząsteczki przeciwciała dla TIM-3 i ich zastosowanie |
| EA201691765A1 (ru) | 2014-03-14 | 2016-12-30 | Новартис Аг | Молекулы антител против lag-3 и их применения |
| EP3191126B1 (en) | 2014-09-13 | 2020-05-13 | Novartis AG | Combination therapies of alk inhibitors |
| KR20170066546A (ko) | 2014-10-03 | 2017-06-14 | 노파르티스 아게 | 조합 요법 |
| TWI706958B (zh) | 2015-03-10 | 2020-10-11 | 美商艾杜諾生物科技公司 | 活化「干擾素基因刺激因子」依賴性訊息傳導之組合物及方法 |
| US20180340025A1 (en) | 2015-07-29 | 2018-11-29 | Novartis Ag | Combination therapies comprising antibody molecules to lag-3 |
| CN108495651A (zh) | 2015-12-17 | 2018-09-04 | 诺华股份有限公司 | 抗pd-1的抗体分子及其用途 |
| EP3507367A4 (en) | 2016-07-05 | 2020-03-25 | Aduro BioTech, Inc. | CYCLIC DINUCLEOTID COMPOUNDS WITH INCLUDED NUCLEIC ACIDS AND USES THEREOF |
| CN106544414A (zh) * | 2016-10-09 | 2017-03-29 | 广州泰诺迪生物科技有限公司 | 一种检测肺癌脑转移样本中stat3和lck的方法 |
| UY37695A (es) | 2017-04-28 | 2018-11-30 | Novartis Ag | Compuesto dinucleótido cíclico bis 2’-5’-rr-(3’f-a)(3’f-a) y usos del mismo |
| CN107137701B (zh) * | 2017-05-07 | 2020-07-14 | 山东兴瑞生物科技有限公司 | 一种提高dc疫苗抗肝癌效果的基因靶标、抑制剂和dc肿瘤疫苗 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5424186A (en) | 1989-06-07 | 1995-06-13 | Affymax Technologies N.V. | Very large scale immobilized polymer synthesis |
| US5143854A (en) | 1989-06-07 | 1992-09-01 | Affymax Technologies N.V. | Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof |
| US20060194275A1 (en) * | 2001-04-13 | 2006-08-31 | Incyte Corporation | Transporter and ion channels |
| JP2012506238A (ja) * | 2008-10-20 | 2012-03-15 | ザ リージェンツ オブ ザ ユニバーシティ オブ コロラド，ア ボディー コーポレイト | インスリン様増殖因子−１受容体キナーゼ阻害剤に対する抗がん反応を予測する生物学的マーカー |
| WO2010141796A2 (en) * | 2009-06-05 | 2010-12-09 | Cephalon, Inc. | PREPARATION AND USES OF 1,2,4-TRIAZOLO [1,5a] PYRIDINE DERIVATIVES |
| EA201390815A1 (ru) * | 2010-12-03 | 2013-12-30 | Им Байосайенсиз Острелиа Пти Лтд. | Лечение jak2-опосредованных состояний |
-
2013
- 2013-07-24 WO PCT/US2013/051824 patent/WO2014018632A1/en not_active Ceased
- 2013-07-24 BR BR112015001521A patent/BR112015001521A2/pt not_active IP Right Cessation
- 2013-07-24 SG SG11201500261VA patent/SG11201500261VA/en unknown
- 2013-07-24 RU RU2015106714A patent/RU2015106714A/ru not_active Application Discontinuation
- 2013-07-24 HK HK15105427.5A patent/HK1205198A1/xx unknown
- 2013-07-24 EP EP13742819.9A patent/EP2877596A1/en not_active Withdrawn
- 2013-07-24 CA CA2880198A patent/CA2880198A1/en not_active Abandoned
- 2013-07-24 KR KR20157004583A patent/KR20150038241A/ko not_active Withdrawn
- 2013-07-24 AU AU2013295855A patent/AU2013295855A1/en not_active Abandoned
- 2013-07-24 JP JP2015524417A patent/JP2015526074A/ja active Pending
- 2013-07-24 CN CN201380040005.0A patent/CN104508149A/zh active Pending
- 2013-07-24 MX MX2015001269A patent/MX2015001269A/es unknown
- 2013-07-24 US US14/417,632 patent/US20150299796A1/en not_active Abandoned
- 2013-07-26 TW TW102126993A patent/TW201409030A/zh unknown
-
2015
- 2015-01-16 TN TNP2015000019A patent/TN2015000019A1/fr unknown
- 2015-01-22 IL IL236897A patent/IL236897A0/en unknown
- 2015-01-26 CL CL2015000192A patent/CL2015000192A1/es unknown
- 2015-01-26 PH PH12015500169A patent/PH12015500169A1/en unknown
-
2017
- 2017-07-14 AU AU2017204894A patent/AU2017204894A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Arbour et al. | Treatment outcomes and clinical characteristics of patients with KRAS-G12C–mutant non–small cell lung cancer | |
| Cui et al. | Ratio of the interferon-γ signature to the immunosuppression signature predicts anti-PD-1 therapy response in melanoma | |
| Wagle et al. | A transcriptional MAPK Pathway Activity Score (MPAS) is a clinically relevant biomarker in multiple cancer types | |
| Hu et al. | The plasma lncRNA acting as fingerprint in non-small-cell lung cancer | |
| Janku et al. | PI3K/AKT/mTOR inhibitors in patients with breast and gynecologic malignancies harboring PIK3CA mutations | |
| Leonard et al. | Practical implications of the 2016 revision of the World Health Organization classification of lymphoid and myeloid neoplasms and acute leukemia | |
| Lara et al. | Predictors of survival for younger patients less than 50 years of age with non-small cell lung cancer (NSCLC): a California Cancer Registry analysis | |
| Buder et al. | The potential of liquid biopsies | |
| Kim et al. | Genomic scoring to determine clinical benefit of immunotherapy by targeted sequencing | |
| Duan et al. | Genetic biomarkers for hepatocellular carcinoma in the era of precision medicine | |
| Yu et al. | CRLF1 promotes malignant phenotypes of papillary thyroid carcinoma by activating the MAPK/ERK and PI3K/AKT pathways | |
| Chien et al. | Targeted BRAF inhibition impacts survival in melanoma patients with high levels of Wnt/β-catenin signaling | |
| JP2016500110A5 (enExample) | ||
| Jørgensen | Companion diagnostics in oncology-current status and future aspects | |
| RU2015106714A (ru) | Прогнозирование ответа на лечение ингибитором jak/stat | |
| Long et al. | Effects of BRAF inhibitors on human melanoma tissue before treatment, early during treatment, and on progression | |
| Shen et al. | LncRNA GHET1 predicts a poor prognosis of the patients with non-small cell lung cancer | |
| Zanoni et al. | Upregulated serum miR‐128‐3p in progressive and relapse‐free multiple sclerosis patients | |
| Faleiro et al. | The TERT hypermethylated oncologic region predicts recurrence and survival in pancreatic cancer | |
| JP2021019631A (ja) | チェックポイント不全およびそれに関する方法 | |
| Olmez et al. | Impact of systemic inflammatory markers in patients with ALK-positive non-small cell lung cancer treated with crizotinib | |
| Breunig et al. | BRaf and MEK inhibitors differentially regulate cell fate and microenvironment in human hepatocellular carcinoma | |
| Hassan-Zahraee et al. | Baseline serum and stool microbiome biomarkers predict clinical efficacy and tissue molecular response after ritlecitinib induction therapy in ulcerative colitis | |
| Grinspan et al. | Biomarker development using liquid biopsy in hepatocellular carcinoma | |
| Elhousiny et al. | Identification of inflammatory mediators associated with metastasis of oral squamous cell carcinoma in experimental and clinical studies: systematic review |